Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000694847 | SCV000823309 | uncertain significance | Hepatic veno-occlusive disease-immunodeficiency syndrome | 2018-06-13 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with SP110-related disease. This variant is reported as two separate single-nucleotide changes in population databases (c.1091C>A, ExAC < 0.01% and c.1092C>T, ExAC < 0.01%). However, in the read data for 3 individuals displayed in the ExAC browser, these two variants are in cis. This recapitulates the variant observed here (c.1091_1092delCCinsAT) and indicates that this variant is very likely present in the population databases at < 0.01%. This sequence change replaces serine with tyrosine at codon 364 of the SP110 protein (p.Ser364Tyr). The serine residue is weakly conserved and there is a large physicochemical difference between serine and tyrosine. |